Patent ID: 7223392

Claim:
A method of treating a human subject having rheumatoid arthritis comprising administering to the human subject a therapeutically effective amount of an anti-human CD23 antibody that (a) binds human CD23; (b) comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of antibody 6G5, wherein CDR1, CDR2, and CDR3 of the light chain of antibody 6G5 are the polypeptides encoded by nucleotides 124–165, 211–231, and 328–357, respectively, of SEQ ID NO:1; and CDR1, CDR2, and CDR3 of the heavy chain of antibody 6G5 are the polypeptides encoded by nucleotides 148–165, 208–258, and 355–390, respectively, of SEQ ID NO:3; and (c) inhibits IL-4-induced IgE production by B-cells.